Patents by Inventor Yong-Jian Geng

Yong-Jian Geng has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11872312
    Abstract: Methods for the treatment of stroke, such as stroke of undetermined origin, by administration of xenon (Xe)-loaded liposome compositions are provided. In some aspects, Xe is encapsulated in echogenic liposomes and release of Xe can be enhanced by application of ultrasound stimulation. Compositions for use in treating stroke, such as liposomes loaded with Xe or Xe in combination with H2 or H2S, are also provided.
    Type: Grant
    Filed: April 13, 2021
    Date of Patent: January 16, 2024
    Assignee: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEMS
    Inventors: Shao-Ling Huang, Melvin E. Klegerman, Yong-Jian Geng, Hyunggun Kim, David D. McPherson
  • Patent number: 11491184
    Abstract: Provided herein is a novel composition for oral administration and delivery of Noble gas, such as xenon or argon. Methods of treating and preventing neuronal or cardiovascular damage with such compositions are also provided.
    Type: Grant
    Filed: December 3, 2019
    Date of Patent: November 8, 2022
    Assignee: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Shao-Ling Huang, David McPherson, Yong-Jian Geng, Xing Yin, Hyunggun Kim, Melvin Klegerman, Tao Peng
  • Publication number: 20220073591
    Abstract: Recombinant clusterin polypeptides and compositions comprising the same are provided. In some aspects, recombinant clusterin or nucleic acids encoding the same may be used for treating and preventing an abnormality of morphology and function in a mammal with disease (e.g., cardiovascular diseases or alcoholism).
    Type: Application
    Filed: August 18, 2021
    Publication date: March 10, 2022
    Applicant: BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventor: Yong-Jian GENG
  • Publication number: 20210378959
    Abstract: Methods for the treatment of stroke, such as stroke of undetermined origin, by administration of xenon (Xe)-loaded liposome compositions are provided. In some aspects, Xe is encapsulated in echogenic liposomes and release of Xe can be enhanced by application of ultrasound stimulation. Compositions for use in treating stroke, such as liposomes loaded with Xe or Xe in combination with H2 or H2S, are also provided.
    Type: Application
    Filed: April 13, 2021
    Publication date: December 9, 2021
    Inventors: Shao-Ling HUANG, Melvin E. KLEGERMAN, Yong-Jian GENG, Hyunggun KIM, David D. MCPHERSON
  • Patent number: 11104719
    Abstract: Recombinant clusterin polypeptides and compositions comprising the same are provided. In some aspects, recombinant clusterin or nucleic acids encoding the same may be used for treating and preventing an abnormality of morphology and function in a mammal with disease (e.g., cardiovascular diseases or alcoholism).
    Type: Grant
    Filed: October 9, 2019
    Date of Patent: August 31, 2021
    Assignee: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventor: Yong-Jian Geng
  • Patent number: 10973764
    Abstract: Methods for the treatment of stroke, such as stroke of undetermined origin, by administration of xenon (Xe)-loaded liposome compositions are provided. In some aspects, Xe is encapsulated in echogenic liposomes and release of Xe can be enhanced by application of ultrasound stimulation. Compositions for use in treating stroke, such as liposomes loaded with Xe or Xe in combination with H2 or H2S, are also provided.
    Type: Grant
    Filed: June 26, 2019
    Date of Patent: April 13, 2021
    Assignee: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Shao-Ling Huang, Melvin E. Klegerman, Yong-Jian Geng, Hyunggun Kim, David D. Mcpherson
  • Publication number: 20200215100
    Abstract: Provided herein is a novel composition for oral administration and delivery of Noble gas, such as xenon or argon. Methods of treating and preventing neuronal or cardiovascular damage with such compositions are also provided.
    Type: Application
    Filed: December 3, 2019
    Publication date: July 9, 2020
    Inventors: Shao-Ling HUANG, David MCPHERSON, Yong-Jian GENG, Xing YIN, Hyunggun KIM, Melvin KLEGERMAN, Tao PENG
  • Patent number: 10639277
    Abstract: Disclosed are multifunctional-echogenic immunoliposome (MF-ELIP) constructs and compositions, and their methods of use to deliver attached stem cells to a target tissue such as atheroma, to enhance one or more of survival, growth, migration, activity and differentiation of the targeted stem cells, for treating, deterring or preventing mammalian atheroma and coronary artery disease.
    Type: Grant
    Filed: February 2, 2018
    Date of Patent: May 5, 2020
    Assignee: BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Yong-Jian Geng, David D. McPherson, Melvin E. Klegerman
  • Publication number: 20200102369
    Abstract: Recombinant clusterin polypeptides and compositions comprising the same are provided. In some aspects, recombinant clusterin or nucleic acids encoding the same may be used for treating and preventing an abnormality of morphology and function in a mammal with disease (e.g., cardiovascular diseases or alcoholism).
    Type: Application
    Filed: October 9, 2019
    Publication date: April 2, 2020
    Inventor: Yong-Jian GENG
  • Publication number: 20200101015
    Abstract: Methods for the treatment of stroke, such as stroke of undetermined origin, by administration of xenon (Xe)-loaded liposome compositions are provided. In some aspects, Xe is encapsulated in echogenic liposomes and release of Xe can be enhanced by application of ultrasound stimulation. Compositions for use in treating stroke, such as liposomes loaded with Xe or Xe in combination with H2 or H2S, are also provided.
    Type: Application
    Filed: June 26, 2019
    Publication date: April 2, 2020
    Inventors: Shao-Ling HUANG, Melvin E. KLEGERMAN, Yong-Jian GENG, Hyunggun KIM, David D. MCPHERSON
  • Patent number: 10464994
    Abstract: Recombinant clusterin polypeptides and compositions comprising the same are provided. In some aspects, recombinant clusterin or nucleic acids encoding the same may be used for treating and preventing an abnormality of morphology and function in a mammal with disease (e.g., cardiovascular diseases or alcoholism).
    Type: Grant
    Filed: December 2, 2015
    Date of Patent: November 5, 2019
    Assignee: BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventor: Yong-Jian Geng
  • Patent number: 10369103
    Abstract: Methods for the treatment of stroke, such as stroke of undetermined origin, by administration of xenon (Xe)-loaded liposome compositions are provided. In some aspects, Xe is encapsulated in echogenic liposomes and release of Xe can be enhanced by application of ultrasound stimulation. Compositions for use in treating stroke, such as liposomes loaded with Xe or Xe in combination with H2 or H2S, are also provided.
    Type: Grant
    Filed: August 9, 2013
    Date of Patent: August 6, 2019
    Assignee: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Shao-Ling Huang, Melvin E. Klegerman, Yong-Jian Geng, Hyunggun Kim, David D. McPherson
  • Publication number: 20180271897
    Abstract: Provided herein is a novel composition for oral administration and delivery of Noble gas, such as xenon or argon. Methods of treating and preventing neuronal or cardiovascular damage with such compositions are also provided.
    Type: Application
    Filed: September 5, 2017
    Publication date: September 27, 2018
    Inventors: Shao-Ling HUANG, David MCPHERSON, Yong-Jian GENG, Xing YIN, Hyunggun KIM, Melvin KLEGERMAN, Tao PENG
  • Publication number: 20160243167
    Abstract: A major risk factor for ischemic heart disease is advanced age. In adult bone marrow and other tissues, the number and function of stem cells decline with aging. Telomerase reverse transcriptase (TERT) is a nuclear protein that decreases senescence. Myocardin (MYOCD) is a transcription factor for myogenesis. Thus a method is provided for the simultaneous delivery of the telomerase reverse transcriptase (TERT) and myocardin MYOCD genes that resuscitates mesenchymal stromal cells (MSCs) from aged adipose and bone marrow tissues by increasing their capacity for survival, proliferation, and differentiation. TERT+/MYOCD+ MSCs restores a capacity for repairing ischemic tissues via improved blood flow and revascularization.
    Type: Application
    Filed: January 13, 2016
    Publication date: August 25, 2016
    Inventors: Yong-Jian GENG, Rosalinda MADONNA, James T. Willerson
  • Publication number: 20160222088
    Abstract: Recombinant clusterin polypeptides and compositions comprising the same are provided. In some aspects, recombinant clusterin or nucleic acids encoding the same may be used for treating and preventing an abnormality of morphology and function in a mammal with disease (e.g., cardiovascular diseases or alcoholism).
    Type: Application
    Filed: December 2, 2015
    Publication date: August 4, 2016
    Inventor: Yong-Jian GENG
  • Publication number: 20160030470
    Abstract: Provided herein is a novel composition for oral administration and delivery of Noble gas, such as xenon or argon. Methods of treating and preventing neuronal or cardiovascular damage with such compositions are also provided. The present invention relates generally to the fields of molecular biology, medicine and nutraceuticals. More particularly, it concerns methods for oral delivery of inert gas compositions, such as Xenon or Argon, for the treatment and prevention of disease.
    Type: Application
    Filed: March 17, 2014
    Publication date: February 4, 2016
    Inventors: Shao-Ling HUANG, David MCPHERSON, Yong-Jian GENG, Xing YIN, Hyunggun KIM, Melvin KLEGERMAN, Tao PENG
  • Publication number: 20150216800
    Abstract: Methods for the treatment of stroke, such as stroke of undetermined origin, by administration of xenon (Xe)-loaded liposome compositions are provided. In some aspects, Xe is encapsulated in echogenic liposomes and release of Xe can be enhanced by application of ultrasound stimulation. Compositions for use in treating stroke, such as liposomes loaded with Xe or Xe in combination with H2 or H2S, are also provided.
    Type: Application
    Filed: August 9, 2013
    Publication date: August 6, 2015
    Applicant: The Board of Regents of the University of Texas Systems
    Inventors: Shao-Ling Huang, Melvin E. Klegerman, Yong-Jian Geng, Hyunggun Kim, David D. McPherson
  • Publication number: 20140065112
    Abstract: A major risk factor for ischemic heart disease is advanced age. In adult bone marrow and other tissues, the number and function of stem cells decline with aging. Telomerase reverse transcriptase (TERT) is a nuclear protein that decreases senescence. Myocardin (MYOCD) is a transcription factor for myogenesis. Thus a method is provided for the simultaneous delivery of the telomerase reverse transcriptase (TERT) and myocardin MYOCD genes that resuscitates mesenchymal stromal cells (MSCs) from aged adipose and bone marrow tissues by increasing their capacity for survival, proliferation, and differentiation. TERT+/MYOCD+ MSCs restores a capacity for repairing ischemic tissues via improved blood flow and revascularization.
    Type: Application
    Filed: August 23, 2013
    Publication date: March 6, 2014
    Applicant: TEXAS HEART INSTITUTE
    Inventors: Rosalinda MADONNA, James T. WILLERSON, Yong-Jian GENG
  • Publication number: 20110171681
    Abstract: Compositions and methods for regulating in vitro cell growth are disclosed, and for providing undifferentiated stem cells or embryonic cells that are suitable for transplantation into damaged tissues or organs, or for use in tissue repair. A representative method includes causing the overexpression or underexpression of GalT binding protein (GtBP), also referred to as GalT associated protein (GTAP), in a cell such that ubiquitination of at least one cellular protein associated with cell adhesion and/or cell-to-cell interaction is correspondingly increased or decreased, causing inhibition of cell growth when GTAP is overexpressed and causing enhanced cell growth when GTAP is underexpressed by the cell. As a result, growth of the cell is altered or regulated.
    Type: Application
    Filed: March 23, 2011
    Publication date: July 14, 2011
    Applicant: BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Yong-Jian GENG, Michael WASSLER
  • Publication number: 20090210956
    Abstract: Methods and compositions are disclosed for inhibiting, deterring or preventing apoptosis of cardiac myocytes, transplanted stem cells, vascular stem cells, and vascular smooth muscle cells by means of expressing or synthesizing clusterin. Also disclosed are methods and compositions for producing recombinant clusterin, or its biologically active peptides, and for induction of clusterin-associated lipoproteins or enzymes for deterring or preventing inflammatory injury and apoptosis induced by oxLDL, oxysterols, cytokines, and Fas Ligand. Also disclosed is an induction method and composition for enhancing expression of ALDH and ALDH-associated enzymes or co-factors to prevent cytotoxicity or detoxification. Therapeutic methods providing new expression or overexpression of clusterin in vascular or cardiac tissue are expected to inhibit the formation of atherosclerotic lesions, stabilize existing atherosclerotic plaques, and repair failing or damaged cardiac tissue.
    Type: Application
    Filed: April 27, 2009
    Publication date: August 20, 2009
    Applicant: BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventor: Yong-Jian GENG